---
title: "GenFleet Therapeutics Schedules Board Meeting to Review Interim Results and Dividend"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295042523.md"
description: "GenFleet Therapeutics (HK:2595) announced that its board will convene on August 21, 2026. The meeting aims to review and approve interim results for the six months ended June 30, 2026, and consider recommending an interim dividend."
datetime: "2026-08-05T22:30:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295042523.md)
  - [en](https://longbridge.com/en/news/295042523.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295042523.md)
generator: "portal-rs"
---

# GenFleet Therapeutics Schedules Board Meeting to Review Interim Results and Dividend

Genfleet Therapeutics (Shanghai), Inc. Class H ( (HK:2595) ) has provided an update.

GenFleet Therapeutics (Shanghai) Inc., a Hong Kong-listed biopharmaceutical company incorporated in the PRC, has a diversified board that includes executive, non-executive and independent non-executive directors led by Chairman and Executive Director Dr. Qiang Lu. The company’s listing under stock code 2595 reflects its access to capital markets to fund its therapeutic development activities.

The company announced that its board will convene on August 21, 2026 to review and approve interim results for the six months ended June 30, 2026 and consider the publication of those results. At the same meeting, directors will also evaluate whether to recommend an interim dividend, a decision that could affect shareholder returns and signal management’s confidence in the firm’s financial performance.

**More about Genfleet Therapeutics (Shanghai), Inc. Class H**

GenFleet Therapeutics (Shanghai) Inc. is a joint stock company incorporated in the People’s Republic of China and listed in Hong Kong under stock code 2595. The company operates in the biopharmaceutical sector, focusing on therapeutic innovation, and is governed by a board comprising executive, non-executive and independent non-executive directors.

The board is chaired by Executive Director Dr. Qiang Lu, with additional executive directors, non-executive directors and independent non-executive directors providing oversight. This governance structure underpins GenFleet Therapeutics’ strategic and financial decision-making as a publicly traded entity.

**Average Trading Volume:** 2,036,789

**Technical Sentiment Signal:** Strong Sell

**Current Market Cap:** HK$10.65B

For a thorough assessment of 2595 stock, go to TipRanks’ Stock Analysis page.

### Related Stocks

- [02595.HK](https://longbridge.com/en/quote/02595.HK.md)

## Related News & Research

- [GenFleet Therapeutics Announces Board Composition and Committee Roles](https://longbridge.com/en/news/300005307.md)
- [GenFleet Advances 2026 H-Share Buyback With Initial Repurchases](https://longbridge.com/en/news/299572840.md)
- [Innometry to attend Kiwoom Securities-hosted corporate day investor briefing](https://longbridge.com/en/news/301521983.md)
- [Wasion Wins ANSI Nod for Smart Meters, Advancing North American Push](https://longbridge.com/en/news/301520170.md)
- [Tencent Plans Professional Investor Note Offering Under MTN Programme](https://longbridge.com/en/news/301520045.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**